Multimodal Treatment Strategy for Locally Advanced Breast Cancer

A. De Matteis, M. Montella, M. Iannuzzo, M. R. De Marco, G. Landi, V. Labonia, P. Frezza, M. Cerra, P. Oliviero, G. D'Aiuto

Research output: Contribution to journalArticlepeer-review


Between 1990 and 1995, 87 patients with locally advanced breast cancer were treated with initial chemotherapy consisting of 3-4 cycles of epirubicin and then with surgery, radiotherapy and chemotherapy. All patients with positive or unknown estrogen receptor status were administered tamoxifen. A complete response was observed in 9 patients and a partial response in 64. At a mean follow-up of 29.22 months, 25 patients had died of metastatic disease, and 48 patients are disease-free. 54% patients are alive at 5 years. Statistical analysis confirmed that neither age, menopausal status, size of the primary tumor nor histology seemed to influence the Disease Free and Overall Survival. Improved survival was observed in patients with negative lymph nodes and positive receptor status. The presence of a positive receptor status may be correlated with conserved integrity of hormone sensitivity and with a good response to the hormone therapy.

Original languageEnglish
Pages (from-to)476-483
Number of pages8
JournalJournal of Chemotherapy
Issue number6
Publication statusPublished - 1998


  • Breast cancer
  • Estrogen receptors
  • Locally advanced breast cancer
  • Neoadjuvant chemotherapy
  • Tamoxifen

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)


Dive into the research topics of 'Multimodal Treatment Strategy for Locally Advanced Breast Cancer'. Together they form a unique fingerprint.

Cite this